{"id":21617,"date":"2026-06-06T12:00:00","date_gmt":"2026-06-06T09:00:00","guid":{"rendered":"https:\/\/otexe.com\/?p=21617"},"modified":"2026-05-30T15:39:35","modified_gmt":"2026-05-30T12:39:35","slug":"curodont-global-rollout-backed-by-apollo","status":"publish","type":"post","link":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/","title":{"rendered":"Curodont global rollout backed by apollo"},"content":{"rendered":"<h1>Apollo minority investment to accelerate vVARDIS\u2019s global rollout of Curodont<\/h1>\n<h2>Introduction \/ background<\/h2>\n<p>ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS\u2019s valuation above US$1.0 billion (\u20ac853.3 million), a threshold frequently referred to as \u201cunicorn\u201d status. Financial terms were not disclosed; the founders and co\u2011CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding.<\/p>\n<h2>What was announced and performed<\/h2>\n<p>The Apollo transaction is intended to support vVARDIS\u2019s next phase of global commercial expansion and continued rollout of its Curodont product line. vVARDIS has been introducing one of its principal products, Curodont Repair Fluoride Plus, in the US market under an exclusive distribution agreement with Henry Schein. The company positioned the investment as a means to strengthen commercial infrastructure across key markets in the US and Europe.<\/p>\n<h2>Key findings and company data<\/h2>\n<ul>\n<li>Valuation: vVARDIS reported a post\u2011transaction valuation of more than US$1.0 billion (\u20ac853.3 million).*<\/li>\n<li>Distribution and uptake in the US: Curodont Repair Fluoride Plus has been rolled out in the US since early 2024 through Henry Schein as exclusive distributor. vVARDIS states the product has been used to treat approximately three million teeth and is now present in nearly 20% of US general dental practices.<\/li>\n<li>Recent financing history: vVARDIS previously secured US$35 million from OrbiMed in February 2025 and an additional US$50 million from OrbiMed in July 2025.<\/li>\n<li>Transaction structure: Apollo\u2019s funds took a strategic minority position; the founders remain majority shareholders. Specific financial details of the Apollo investment were not released.<\/li>\n<\/ul>\n<h2>Representative statements<\/h2>\n<blockquote>\n<p>Jeremy Honeth, partner at Apollo: \u201cDrs Haley and Goly Abivardi had pioneered \u2018a new category in dental care\u2019, backed by peer\u2011reviewed clinical studies, and built vVARDIS into \u2018a differentiated business\u2019. Apollo\u2019s investment supports the company\u2019s continued expansion in key markets across the US and Europe, bringing this restorative therapy to more practices and patients worldwide.\u201d<\/p>\n<\/blockquote>\n<blockquote>\n<p>Dr Haley Abivardi: \u201cCurodont fills a longstanding gap in dentistry: when prevention fails, dentists now have a quick, easy\u2011to\u2011use non\u2011invasive treatment. The rapid adoption of Curodont reflects the urgency of that unmet need. Apollo\u2019s investment will strengthen our commercial foundation in the US and Europe and will enable us to scale this environmentally sustainable technology across markets.\u201d<\/p>\n<\/blockquote>\n<blockquote>\n<p>Dr Goly Abivardi: \u201cOur mission is to bring a medical, science\u2011driven approach to dentistry. Using peptide\u2011containing formulations, our non\u2011invasive technology is an innovative treatment designed to treat caries without drilling and without polymer materials. Apollo\u2019s investment reinforces our leadership in generative dentistry and advances the future of oral science.\u201d<\/p>\n<\/blockquote>\n<h2>Relevance for dental practice<\/h2>\n<p>For clinicians, the announcement signals continued commercial backing for a non\u2011invasive, peptide\u2011based approach to managing early carious lesions. In the US, Curodont Repair Fluoride Plus is already distributed exclusively through Henry Schein and, according to vVARDIS, has seen measurable uptake across general practices. The investment may accelerate wider availability and commercial support, but clinical adoption should continue to be guided by peer\u2011reviewed evidence and individual practice protocols.<\/p>\n<h2>Limitations and context<\/h2>\n<ul>\n<li>The company\u2019s valuation figure was provided by vVARDIS and the conversion to euros is noted as calculated on the OANDA platform for 27 April 2026.<\/li>\n<li>Detailed financial terms of the Apollo minority investment were not disclosed.<\/li>\n<li>Statements regarding product use and market penetration are reported by the company; independent verification is not provided in the announcement.<\/li>\n<\/ul>\n<h2>SOURCE<\/h2>\n<p><a href=\"https:\/\/www.dental-tribune.com\/news\/apollo-investment-supports-vvardiss-global-curodont-expansion\/\"><\/a>https:\/\/www.dental-tribune.com\/news\/apollo-investment-supports-vvardiss-global-curodont-expansion\/<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apollo minority investment to accelerate vVARDIS\u2019s global rollout of Curodont Introduction \/ background ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":21615,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"pmpro_default_level":"","footnotes":""},"categories":[266],"tags":[],"class_list":["post-21617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-in-dentistry","pmpro-has-access"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Curodont global rollout backed by apollo - OTEXE<\/title>\n<meta name=\"description\" content=\"ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS\u2019s valuation above US$1.0 billion (\u20ac853.3 million), a threshold frequently referred to as \u201cunicorn\u201d status. Financial terms were not disclosed; the founders and co\u2011CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curodont global rollout backed by apollo - OTEXE\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS\u2019s valuation above US$1.0 billion (\u20ac853.3 million), a threshold frequently referred to as \u201cunicorn\u201d status. Financial terms were not disclosed; the founders and co\u2011CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/\" \/>\n<meta property=\"og:site_name\" content=\"OTEXE\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/otexeworld\/reviews\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-06T09:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"news bot\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@otexeworld\" \/>\n<meta name=\"twitter:site\" content=\"@otexeworld\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"news bot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/\"},\"author\":{\"name\":\"news bot\",\"@id\":\"https:\/\/otexe.com\/en\/#\/schema\/person\/9140d95fa9a582da764836aeeea66419\"},\"headline\":\"Curodont global rollout backed by apollo\",\"datePublished\":\"2026-06-06T09:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/\"},\"wordCount\":601,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/otexe.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg\",\"articleSection\":[\"New in Dentistry\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/\",\"url\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/\",\"name\":\"Curodont global rollout backed by apollo - OTEXE\",\"isPartOf\":{\"@id\":\"https:\/\/otexe.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg\",\"datePublished\":\"2026-06-06T09:00:00+00:00\",\"description\":\"ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS\u2019s valuation above US$1.0 billion (\u20ac853.3 million), a threshold frequently referred to as \u201cunicorn\u201d status. Financial terms were not disclosed; the founders and co\u2011CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding.\",\"breadcrumb\":{\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#primaryimage\",\"url\":\"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg\",\"contentUrl\":\"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Main\",\"item\":\"https:\/\/otexe.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New in Dentistry\",\"item\":\"https:\/\/otexe.com\/en\/category\/new-in-dentistry\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Curodont global rollout backed by apollo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/otexe.com\/en\/#website\",\"url\":\"https:\/\/otexe.com\/en\/\",\"name\":\"OTEXE\",\"description\":\"Is a community where the best minds in dentistry are creating the future of the industry\",\"publisher\":{\"@id\":\"https:\/\/otexe.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/otexe.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/otexe.com\/en\/#organization\",\"name\":\"Otexe\",\"url\":\"https:\/\/otexe.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/otexe.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/otexe.com\/wp-content\/uploads\/2025\/07\/logo.png\",\"contentUrl\":\"https:\/\/otexe.com\/wp-content\/uploads\/2025\/07\/logo.png\",\"width\":697,\"height\":697,\"caption\":\"Otexe\"},\"image\":{\"@id\":\"https:\/\/otexe.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/otexeworld\/reviews\",\"https:\/\/x.com\/otexeworld\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/otexe.com\/en\/#\/schema\/person\/9140d95fa9a582da764836aeeea66419\",\"name\":\"news bot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/otexe.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/126946fb002d82862ee4daf1c3c87cd017acab2d58cb90a684793b86e7347e3d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/126946fb002d82862ee4daf1c3c87cd017acab2d58cb90a684793b86e7347e3d?s=96&d=mm&r=g\",\"caption\":\"news bot\"},\"url\":\"https:\/\/otexe.com\/en\/author\/news-bot\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curodont global rollout backed by apollo - OTEXE","description":"ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS\u2019s valuation above US$1.0 billion (\u20ac853.3 million), a threshold frequently referred to as \u201cunicorn\u201d status. Financial terms were not disclosed; the founders and co\u2011CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/","og_locale":"en_US","og_type":"article","og_title":"Curodont global rollout backed by apollo - OTEXE","og_description":"ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS\u2019s valuation above US$1.0 billion (\u20ac853.3 million), a threshold frequently referred to as \u201cunicorn\u201d status. Financial terms were not disclosed; the founders and co\u2011CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding.","og_url":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/","og_site_name":"OTEXE","article_publisher":"https:\/\/www.facebook.com\/otexeworld\/reviews","article_published_time":"2026-06-06T09:00:00+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg","type":"image\/jpeg"}],"author":"news bot","twitter_card":"summary_large_image","twitter_creator":"@otexeworld","twitter_site":"@otexeworld","twitter_misc":{"Written by":"news bot","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#article","isPartOf":{"@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/"},"author":{"name":"news bot","@id":"https:\/\/otexe.com\/en\/#\/schema\/person\/9140d95fa9a582da764836aeeea66419"},"headline":"Curodont global rollout backed by apollo","datePublished":"2026-06-06T09:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/"},"wordCount":601,"commentCount":0,"publisher":{"@id":"https:\/\/otexe.com\/en\/#organization"},"image":{"@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#primaryimage"},"thumbnailUrl":"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg","articleSection":["New in Dentistry"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/","url":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/","name":"Curodont global rollout backed by apollo - OTEXE","isPartOf":{"@id":"https:\/\/otexe.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#primaryimage"},"image":{"@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#primaryimage"},"thumbnailUrl":"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg","datePublished":"2026-06-06T09:00:00+00:00","description":"ZUG, Switzerland \u2014 vVARDIS, the privately held Swiss medical\u2011technology company behind the peptide\u2011based Curodont technology for non\u2011invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS\u2019s valuation above US$1.0 billion (\u20ac853.3 million), a threshold frequently referred to as \u201cunicorn\u201d status. Financial terms were not disclosed; the founders and co\u2011CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding.","breadcrumb":{"@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#primaryimage","url":"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg","contentUrl":"https:\/\/otexe.com\/wp-content\/uploads\/2026\/05\/apollo-investment-supports-vvardiss-global-curodont-expansion_1.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/otexe.com\/en\/curodont-global-rollout-backed-by-apollo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Main","item":"https:\/\/otexe.com\/en\/"},{"@type":"ListItem","position":2,"name":"New in Dentistry","item":"https:\/\/otexe.com\/en\/category\/new-in-dentistry\/"},{"@type":"ListItem","position":3,"name":"Curodont global rollout backed by apollo"}]},{"@type":"WebSite","@id":"https:\/\/otexe.com\/en\/#website","url":"https:\/\/otexe.com\/en\/","name":"OTEXE","description":"Is a community where the best minds in dentistry are creating the future of the industry","publisher":{"@id":"https:\/\/otexe.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/otexe.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/otexe.com\/en\/#organization","name":"Otexe","url":"https:\/\/otexe.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/otexe.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/otexe.com\/wp-content\/uploads\/2025\/07\/logo.png","contentUrl":"https:\/\/otexe.com\/wp-content\/uploads\/2025\/07\/logo.png","width":697,"height":697,"caption":"Otexe"},"image":{"@id":"https:\/\/otexe.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/otexeworld\/reviews","https:\/\/x.com\/otexeworld"]},{"@type":"Person","@id":"https:\/\/otexe.com\/en\/#\/schema\/person\/9140d95fa9a582da764836aeeea66419","name":"news bot","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/otexe.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/126946fb002d82862ee4daf1c3c87cd017acab2d58cb90a684793b86e7347e3d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/126946fb002d82862ee4daf1c3c87cd017acab2d58cb90a684793b86e7347e3d?s=96&d=mm&r=g","caption":"news bot"},"url":"https:\/\/otexe.com\/en\/author\/news-bot\/"}]}},"_links":{"self":[{"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/posts\/21617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/comments?post=21617"}],"version-history":[{"count":2,"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/posts\/21617\/revisions"}],"predecessor-version":[{"id":21620,"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/posts\/21617\/revisions\/21620"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/media\/21615"}],"wp:attachment":[{"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/media?parent=21617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/categories?post=21617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/otexe.com\/en\/wp-json\/wp\/v2\/tags?post=21617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}